MRD Testing Could Cut Costs, Refine Blood Cancer Care: Ravi Vij, MD, MBA
Written by
American Journal Managed Care
Published
0
comments
0
min
Ravi Vij, MD, MBA, discusses how measurable residual disease (MRD) testing is shaping treatment decisions in hematology and its potential to reduce costs and toxicity.